JP2023022236A5 - - Google Patents

Download PDF

Info

Publication number
JP2023022236A5
JP2023022236A5 JP2022192727A JP2022192727A JP2023022236A5 JP 2023022236 A5 JP2023022236 A5 JP 2023022236A5 JP 2022192727 A JP2022192727 A JP 2022192727A JP 2022192727 A JP2022192727 A JP 2022192727A JP 2023022236 A5 JP2023022236 A5 JP 2023022236A5
Authority
JP
Japan
Prior art keywords
optionally substituted
membered ring
ring containing
formula
liver disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022192727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023022236A (ja
Filing date
Publication date
Priority claimed from JP2019512804A external-priority patent/JP7189127B2/ja
Application filed filed Critical
Publication of JP2023022236A publication Critical patent/JP2023022236A/ja
Publication of JP2023022236A5 publication Critical patent/JP2023022236A5/ja
Priority to JP2024213390A priority Critical patent/JP2025032245A/ja
Pending legal-status Critical Current

Links

JP2022192727A 2016-09-06 2022-12-01 非アルコール性脂肪性肝疾患(nafld)、nash、aldまたは肝臓に関する状態の治療、予防または改善のためのガンマ-ケトアルデヒドスカベンジャーの組成物および使用方法 Pending JP2023022236A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024213390A JP2025032245A (ja) 2016-09-06 2024-12-06 非アルコール性脂肪性肝疾患(nafld)、nash、aldまたは肝臓に関する状態の治療、予防または改善のためのガンマ-ケトアルデヒドスカベンジャーの組成物および使用方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662383895P 2016-09-06 2016-09-06
US62/383,895 2016-09-06
US201662410133P 2016-10-19 2016-10-19
US62/410,133 2016-10-19
JP2019512804A JP7189127B2 (ja) 2016-09-06 2017-09-06 非アルコール性脂肪性肝疾患(nafld)、nash、aldまたは肝臓に関する状態の治療、予防または改善のためのガンマ-ケトアルデヒドスカベンジャーの組成物および使用方法
PCT/US2017/050317 WO2018048932A1 (en) 2016-09-06 2017-09-06 Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019512804A Division JP7189127B2 (ja) 2016-09-06 2017-09-06 非アルコール性脂肪性肝疾患(nafld)、nash、aldまたは肝臓に関する状態の治療、予防または改善のためのガンマ-ケトアルデヒドスカベンジャーの組成物および使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024213390A Division JP2025032245A (ja) 2016-09-06 2024-12-06 非アルコール性脂肪性肝疾患(nafld)、nash、aldまたは肝臓に関する状態の治療、予防または改善のためのガンマ-ケトアルデヒドスカベンジャーの組成物および使用方法

Publications (2)

Publication Number Publication Date
JP2023022236A JP2023022236A (ja) 2023-02-14
JP2023022236A5 true JP2023022236A5 (https=) 2023-03-16

Family

ID=61562136

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019512804A Active JP7189127B2 (ja) 2016-09-06 2017-09-06 非アルコール性脂肪性肝疾患(nafld)、nash、aldまたは肝臓に関する状態の治療、予防または改善のためのガンマ-ケトアルデヒドスカベンジャーの組成物および使用方法
JP2022192727A Pending JP2023022236A (ja) 2016-09-06 2022-12-01 非アルコール性脂肪性肝疾患(nafld)、nash、aldまたは肝臓に関する状態の治療、予防または改善のためのガンマ-ケトアルデヒドスカベンジャーの組成物および使用方法
JP2024213390A Pending JP2025032245A (ja) 2016-09-06 2024-12-06 非アルコール性脂肪性肝疾患(nafld)、nash、aldまたは肝臓に関する状態の治療、予防または改善のためのガンマ-ケトアルデヒドスカベンジャーの組成物および使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019512804A Active JP7189127B2 (ja) 2016-09-06 2017-09-06 非アルコール性脂肪性肝疾患(nafld)、nash、aldまたは肝臓に関する状態の治療、予防または改善のためのガンマ-ケトアルデヒドスカベンジャーの組成物および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024213390A Pending JP2025032245A (ja) 2016-09-06 2024-12-06 非アルコール性脂肪性肝疾患(nafld)、nash、aldまたは肝臓に関する状態の治療、予防または改善のためのガンマ-ケトアルデヒドスカベンジャーの組成物および使用方法

Country Status (8)

Country Link
US (3) US20180153827A1 (https=)
EP (1) EP3510014B1 (https=)
JP (3) JP7189127B2 (https=)
CN (2) CN110177771B (https=)
AU (1) AU2017324935B2 (https=)
CA (1) CA3035897A1 (https=)
MX (1) MX2019002579A (https=)
WO (1) WO2018048932A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389414B2 (en) 2017-04-27 2022-07-19 Vanderbilt University Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers
AU2018330416B2 (en) * 2017-09-05 2024-09-26 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving fibrosis of the liver
ES3025857T3 (en) * 2019-01-25 2025-06-09 Mti Biotech Inc Triphenylphosphonium-tethered salicylamine derivatives
CN114344448A (zh) * 2022-01-20 2022-04-15 广西医科大学第一附属医院 Pmx-53多肽在制备治疗非酒精性脂肪性肝炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2347117C (en) 1998-10-22 2006-01-24 University Of South Carolina Methods for inhibiting diabetic complications
EP1177796B1 (en) * 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Medicament for prevention or therapeutic treatment of liver disease
CN1628650A (zh) * 2003-12-19 2005-06-22 刘力 复方二氯醋酸二异丙胺冻干粉针制剂及其制备方法
US8822542B2 (en) * 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
WO2008070778A2 (en) * 2006-12-06 2008-06-12 Nephrogenex Inc. Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease
KR101209319B1 (ko) * 2008-04-29 2012-12-06 한올바이오파마주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
MX383365B (es) 2011-07-12 2025-03-13 Univ Vanderbilt Metodos para tratar inflamacion e hipertension con eliminadores de gama-cetoaldehidos.
US20150087660A1 (en) * 2012-05-10 2015-03-26 Mahesh Kandula Compositions and methods for the treatment of chronic diseases and inflammatory disorders
US20150265584A1 (en) 2014-03-18 2015-09-24 Vanderbilt University Levuglandin adducts histone h4 in a cyclooxygenase-2-dependent manner, altering its interaction with dna
JP2017537149A (ja) 2014-11-11 2017-12-14 ヴァンダービルト ユニバーシティー 急性腎傷害を制限するための方法
WO2017033119A1 (en) * 2015-08-25 2017-03-02 Rao M Surya Compositions and methods for the treatment of liver metabolic diseases
US20210023032A1 (en) * 2017-09-05 2021-01-28 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
AU2018330416B2 (en) * 2017-09-05 2024-09-26 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving fibrosis of the liver

Similar Documents

Publication Publication Date Title
JP2023022236A5 (https=)
JP2024514837A5 (https=)
JP2024516371A5 (https=)
JP2011504935A5 (https=)
JP2013541514A5 (https=)
JP2006509749A5 (https=)
JP2017214387A5 (https=)
JP2010532768A5 (https=)
JP2010504346A5 (https=)
JP2012532883A5 (https=)
JP2010523476A5 (https=)
RU2005107314A (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью
JP2011529502A5 (https=)
JP2014528464A5 (https=)
JP2002030084A5 (https=)
JP2017505293A5 (https=)
JP2010090149A5 (https=)
RU2367650C2 (ru) Циклоалкендикарбоновые кислоты как противовоспалительные, иммуномодулирующие и антипролиферативные средства
RU2017131354A (ru) Замещенные амино шестичленные насыщенные гетероалициклы в качестве ингибиторов dpp-iv длительного действия
JP2015536974A5 (https=)
JP2008534453A5 (https=)
JP2002527414A5 (https=)
JP2007502817A5 (https=)
CA2533747A1 (en) Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors
TW201912153A (zh) 用於治療b型肝炎的化合物、醫藥組合物及方法